SUMMARY
GAS6, the product of a growth arrest specific gene (GAS), is the ligand of the tyrosine kinase receptor Axl. GAS6 and Axl are both expressed in endothelial cells, were they are involved in many processes such as leukocyte transmigration through capillaries and neointima formation in injured vessels. Here 
INTRODUCTION
Axl is a 140 kD protein which belongs to a subfamily of tyrosine kinase receptor (RTK) that includes also Mer and Rse. These receptors are characterized by the presence of two immunoglobulin-like domains and two fibronectin-type III domains in the extracellular region and a distinctive intracellular kinase domain [1] [2] [3] . Axl was first isolated from the DNA of patients with chronic myelogenous leukaemia but subsequently its expression was demonstrated in mammalian cells of vascular, immune and reproductive systems 1, [4] [5] [6] . Axl is involved in cell-cell aggregation 7 , in the tropic maintenance of a wide variety of cell types in adult tissues 6 and in homeostatic regulation of immune system 8 .
GAS6, a protein codified by a growth arrest specific gene, is a member of the vitamin K-dependent protein family. GAS6 has 42% aminoacid identity to protein S, a serum protein that negatively regulates blood coagulation. GAS6 is composed of characteristic structural motifs: a γ-carboxylated amino-terminus domain followed by four epidermal growth factor-like domains and by a set of tandem G domains related to those of sex hormone binding globulin 9 . GAS6 binds with different affinities and activates the kinase activity of each Axl family member [10] [11] [12] . GAS6 shows the higher affinity for Axl, and its interaction generally triggers anti-apoptotic signals resulting in an augmented cell survival. In some cell types it regulates homo-and hetero-typic adhesion 4, 13 , promotes proliferation 5, 14 , survival [15] [16] [17] [18] and motility 19, 20 , amplifies the activity of extracellular stimuli 21, 22 .
Vasculature may be a target of GAS6/Axl axis, being both molecules expressed by endothelial cells (EC) 4,9 , pericytes 23 and smooth muscle cells 24 .
GAS6/Axl interaction is involved in leukocyte transmigration through capillaries 4, 8 , in neointima formation in injured vessels 24 , in EC survival after TNF-α treatment or Perkin Elmer, Cetus, Norwalk, CT) was used for detection.
Binding displacement assay
The binding of VEGF-A 165 with its high affinity sites on ECs reaches the equilibrium after 90 min at room temperature 39 . On the basis of this data, binding displacement studies with GAS6 were performed. Cell monolayers on 24-well plates were incubated for 90 min at room temperature in 0.2 ml M199 containing 20 mM HEPES, pH 7.4, 0.1% bovine serum albumin, 100 µg/mL soybean trypsin inhibitor (Sigma-Aldrich) with 
RESULTS

GAS6 activates Axl receptor and inhibits VEGF-A -dependent chemotaxis of ECs.
Stimulation of EC motility is a necessary, and in some cases sufficient, step of vascular pattern formation [40] [41] [42] . Therefore we examined the effect of GAS6 on in vitro EC chemotaxis. GAS6 was ineffective in promoting EC directional migration but consistently inhibited in a dose-dependent fashion the chemotactic effect of optimal concentration of VEGF-A 165 and VEGF-A 121 ( Fig. 1 A) . One ng/mL of GAS6 inhibited at 50% the chemotaxis induced by 10 ng/mL of VEGF-A 165 and was used in successive experiments. The presence in the chemotaxis assay of a soluble Ig fusion protein containing the Axl extracellular domain (Axl-Ig) or a polyclonal Ab directed toward the N-terminus extremity of Axl (αAxl-N) 12 blocked the effect of GAS6 demonstrating that Axl is the RTK engaged by GAS6 ( Fig. 1 B) . GAS6 used at 1 ng/mL (Fig. 1C ) or at higher concentrations (from 10 ng/mL up to 500 ng/mL) (not shown) did not influence the chemotactic activity of FGF-2 and HGF, suggesting that it specifically inhibits the effect of VEGF-A. GAS6 induced the autophosphorylation in tyrosine residues of Axl immunoprecipitated by ECs, being active at 1 ng/mL. This activity was abolished by the presence of the decoy receptor Axl-Ig (Fig. 1D) .
only.
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GAS6 inhibits the autonomous property of ECs to form capillary-like nets
ECs cultured on Matrigel, a natural basal membrane matrix, spontaneous differentiate in geometric tubular networks independently from cell mitosis 42 . This process requires directed cell migration governed by the presence of VEGF-A, which mainly acts in paracrine/autocrine manner, as inferred by the inhibitory effect exerted by an Ab anti-VEGF-A 42 . As shown in Figure 2 , the presence of GAS6 impaired the morphogenetic potential of ECs on Matrigel in a dose dependent manner and the maximal inhibitory effect was obtained at 80-100 ng/mL (Fig.2B ). In the presence of GAS6, ECs were unable to form cords interconnected with nodes, and remained mostly sparse with few chains formed. The addition of Axl-Ig reverted the GAS6 effect, while
Axl-Ig alone was ineffective ( Fig.2A ).
GAS6 inhibits VEGF-A -dependent vascularization in CAM assay
The in vivo inhibitory effect of GAS6 on vascular formation was demonstrated in the CAM assay ( Fig.3 and Table 1 ). The gelatin sponges treated with VEGF-A 165 (50 ng) were surrounded by allantoic vessels radiating towards the implant in a 'spokedwheel' pattern ( Fig. 3a) , while GAS6 used at 50 ng/sponge was ineffective (Fig. 3b ).
GAS6 did not promote vascularization in a range from 1 ng to 500 ng (data not shown).
In contrast, GAS6 used at 20 ng/sponge was able to inhibit the activity of VEGF-A 165 (Fig. 3c, Table 1 ), but not that of FGF-2 ( Table 1 ). The presence of the decoy receptor Axl-Ig allowed VEGF-A 165 inducing angiogenesis, supporting the direct involvement of GAS6-Axl axis in the control of the vascularization mediated by VEGF-A ( Fig. 3d and Table 1 ).
GAS6 inhibits autophosphorylation of VEGFR-2 induced by VEGF-A.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Autophosphorylation in tyrosine residues is the earliest event occurring after VEGF-Adependent VEGFR-2 dimerization 29 . To explore the mechanism by which GAS6 affected VEGF-A activities, VEGFR-2 was immunoprecipitated from ECs and analysed for its phosphorylation state. Figure 4 shows that a short pre-incubation of ECs with GAS6 at 1 ng/mL resulted in a marked inhibition of VEGFR-2 autophosphorylation. To evaluate a possible cross talk between VEGFR-2 and Axl, ECs were stimulated as in the previous experiment and the lysates were immunoprecipitated with a mAb anti-P-Tyr. As shown in Figure 4B , the presence of VEGF-A 165 did not affect Axl phosphorylation.
To exclude that the observed inhibition of VEGFR-2 phosphorylation may be the consequence of a competitive mechanisms we studied the effect of 
Tyrosine phosphatase SHP-2 is involved in the inhibitory activity of GAS6 on VEGF-A -mediated EC activation.
It is well established that cytosolic protein tyrosine phosphatases containing src homology domain-2 (SHP) regulate intracellular pathways activated by several receptors including RTK 44,45 . SHP-2 has been implicated in the signalling pathways triggered by VEGF-A 46 , and our preliminary results indicate that it dephosphorylates VEGFR-2 in vitro (S. Mitola in preparation). Therefore we tested the hypothesis that SHP-2 could be responsible of the inhibitory signal mediated by GAS6-Axl axis on only.
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Phosphorylation occurred within 5 min and persisted up to 30 min.
Therefore ECs were infected with a retroviral vector carrying SHP-2 C/S, the catalytically inactive Cys-to-Ser mutant form 47 ( Fig. 2A) . The expression of this mutant did not modify the GAS6-dependent Axl phosphorylation. (Fig.7B) . Furthermore, the expression of SHP-2 C/S mutant was able to suppress SHP-2 phosphorylation triggered by GAS6. This is a surprising result because the point mutation in SHP-2 C/S does not involve the SH-2 domain and therefore the enzyme may associate to Axl. It is possible to speculate that due to the high expression levels of SHP-2 obtained by a high efficiency retroviral infection system as compared to the endogenous enzyme levels, the relative amount of SHP-2 becomes phosphorylated by endogenous levels of Axl tyrosine kinase is reduced, and is not detected by immunoprecipitation followed by
immunoblotting.
An essentially confirmation of the role of this phosphatase as the effector of GAS6 on VEGFR-2 was inferred by the lack of the inhibitory effect of GAS6 on VEGFR-2 phosphorylation in ECs expressing SHP-2C/S and stimulated by VEGF-A 165 (Fig 7C) . Figure 7D shows that GAS6 inhibited EC chemotaxis induced by VEGF-A 121 and VEGF-A 165 . The expression of the SHP-2 mutant abrogated this effect substantiating that this phosphatase is involved the negative signalling exerted by GAS6 on VEGF-A.
For . In ECs, high concentrations of GAS6 (100 -800 ng/ml) exert an antiapoptotic effect and inhibit neutrophil adhesion 4,16,18 and has been suggested that it impacts on the response of blood vessels to injury, thereby contributing to the development of atherosclerosis and/or restenosis 48 . Finally, GAS6 has been detected in inflammatory diseases 18, 49 and in human cancers 50,51 but the exact significance of its presence is largely elusive.
In the present study we describe a GAS6 -dependent inhibitory pathway, which 58 . This is a nuclear antiapoptotic factor, which inhibits migration of smooth muscle cells in vitro. In a model of experimental angioplasty fortilin reduces neointima formation through powerful antiproliferative and anti-migratory actions concomitant with the ability to reduce vascular cell apoptosis and maintain vessel wall integrity 58 .
The tyrosine phosphatase SHP-2 is widely expressed and can both positively or negatively regulates signalling pathways depending upon the specific type of signalling network 44, 45 . For example, SHP-2 acts as a negative regulator in signalling pathways related to platelet derived growth factor receptor, epidermal growth factor receptor, T cell receptor and angiotensin II receptor [59] [60] [61] [62] [63] . In FGF and insulin signalling pathways, SHP-2 instead acts as a positive regulator 64, 65 . This enzyme has been shown to exert only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From both negative and positive influences on the Janus kinase/ signal transducers and activators of transcription pathway that is activated by different cytokines 66, 67 . Our results showing that the dominant negative mutant of SHP-2 reverts the inhibitory effects of GAS6, suggest that this phosphatase activated by GAS6 is involved in inhibiting the activities of VEGF-A. This observation parallels the results that VEGFR-2 may be negatively regulated by tumor necrosis factor-α or by tissue inhibitor of metalloproteinases-2 (TIMP-2) through SHP-1 68, 69 . The present study does not investigate the precise mechanism by which VEGFR-2 is inactivated by GAS6. It is intriguing to speculate on a direct effect of SHP-2 on VEGFR-2. In EC stimulated by TIMP-2 SHP-1, which is another member of this tyrosine phosphatase family, dephosphorylates VEGFR-2 by shifting from α3β1 integrin to the receptor 69 .
Alternatively we may hypothesize an indirect effect mediated by other tyrosine phosphatases, including HCPTPA. By yeast two-hybrid system this phosphatase has been identified to be a specific partner of VEGFR-2 and able to cause its dephosphorylation 70 .
Our results cannot exclude that the participation of SHP-2 in GAS6 -dependent inhibition of EC motility exclusively occurs in interfering VEGFR-2 -triggered signals.
Actually cells derived from SHP-2 -/-mice or expressing a SHP-2 dominant negative mutant display severe defects in spreading, haptotactic and chemotactic response [71] [72] [73] , being this phosphatase involved in adhesion site dynamics 53, 74 .
A large number of strategies occur to counteract the effect of angiogenic inducers and a right balance between inhibitors and agonists is instrumental in formation of an accurate vasculature in embryonic and adult tissues 27, 75 . Inhibition or regression of angiogenic process takes place in absence of an adequate blood flow 75 79 . With the exception of decoy receptors, these inhibitory mechanisms are generally broad and impair EC function related to angiogenesis (i.e. migration, survival, proliferation) independently from stimuli. Our results suggest that GAS6-Axl axis represents a specific inhibitory pathway for VEGF-A -mediated angiogenesis.
Interfering in VEGF-A -mediated signals seems to be the first promising application of anti-angiogenic therapy in human cancers 81, 82 . Therefore, delineation of a selective mechanism that turns-off VEGFR-2 may facilitate the design of further and effective combination therapies for disruption of vascular network in tumours. However, in the light of limited knowledges on the role played by GAS in human and experimental diseases, our results need further validations in specific animal models. only.
